Rosen Law Firm has filed a class action lawsuit against Lincoln Educational Services Corporation for allegedly making false and misleading statements about its student admissions process between May 11 and August 9, 2026. The lawsuit claims Lincoln misrepresented its ability to convert student enrollments into actual starts, causing investors to suffer losses when the truth emerged. Investors who bought Lincoln securities during this period may join the lawsuit and seek compensation without upfront fees. Interested parties must act by November 10, 2026, to become lead plaintiff in the case.
Lincoln Educational Services Corporation securities fraud lawsuit is the subject, with Pluang's Consumer Cyclical sector data providing market context. For readers following this sector, as of Sep 16, 2026 02:31 WIB, 10 of 105 priced US stocks rose while 95 fell. Notable movers include Allbirds Inc (BIRD) at USD 2.37 down 5.58%, Stitch Fix Inc (SFIX) at USD 2.93 down 5.18%, and Kohl's Corporation (KSS) at USD 16.32 down 4.90%.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
